|Bid||0.00 x 1100|
|Ask||0.00 x 800|
|Day's Range||309.97 - 327.39|
|52 Week Range||155.16 - 388.97|
|Beta (5Y Monthly)||0.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 07, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||362.33|
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that its PARP inhibitor pamiparib has received conditional approval from the China National Medical Products Administration (NMPA) for the treatment of patients with germline BRCA (gBRCA) mutation-associated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more lines of chemotherapy. The new drug application was previously granted priority review by the Center for Drug Evaluation (CDE) in July 2020. BeiGene is preparing to launch pamiparib this month.
BeiGene reported recent business highlights, anticipated upcoming milestones, and financial results for the first quarter of 2021.
BeiGene Ltd (NASDAQ: BGNE) announced positive results from a planned interim analysis of the Phase 3 ALPINE trial comparing Brukinsa (zanubrutinib) against Johnson & Johnson's (NYSE: JNJ) Imbruvica (ibrutinib) in adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The data is based on 415 of 652 patients followed for a minimum of 12 months. The planned final analysis is expected in 2022. Brukinsa met the primary endpoint of the trial, demonstrating non-inferiority in objective response rate (ORR) vs. ibrutinib by investigator assessment and a numerically higher ORR but not statistically significant improvement by the independent review committee. The trial also met a prespecified secondary endpoint related to safety, and Brukinsa demonstrated a statistically significant lower risk of atrial fibrillation or flutter versus ibrutinib. BeiGene plans to present these data at an upcoming major medical conference. Price Action: BGNE shares are up 9.2% at $353.25 during market trading hours on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaEli Lilly Abandons IL-23 Psoriasis Program, Instead Will Focus On Ulcerative Colitis, Crohn's Disease IndicationsUS To Share Up To 60M AstraZeneca COVID-19 Vaccine Doses© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.